von Tobias Borgers | Nov. 23, 2023 | Boehringer
BI 764532 was discovered using OBT’s proprietary OGAP® platform, the world’s largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets Oxford, UK, San Jose, Calif., 24th October 2023 – Oxford...
von Tobias Borgers | Nov. 15, 2023 | Boehringer
German biopharmaceutical company Boehringer Ingelheim“s China arm inked a strategic cooperation agreement with Chinese high-tech company ChromX Health during the recently-concluded sixth China International Import Expo in Shanghai. German biopharmaceutical...
von Tobias Borgers | Okt. 12, 2023 | Boehringer
ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) — The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member. Boehringer Ingelheim...
von Tobias Borgers | Okt. 12, 2023 | Boehringer
Biberach (ots)Ein Labor so groß wie fünf Fußballfelder und Investitionen in Höhe von 350 Mio. Euro: Der Pharmariese Boehringer Ingelheim, Deutschlands zweitgrößter Arzneimittelhersteller, hat im baden-württembergischen Biberach ein neues Entwicklungszentrum für...
von Tobias Borgers | Sep. 29, 2023 | Boehringer
Im April 2022 hat der deutsche Pharma-Riese Boehringer Ingelheim (53.100 Mitarbeiter, 24,1 Milliarden Euro Umsatz) entschieden, dass eine neue Produktionsstätte in Bruck an der Leitha, Niederösterreich, errichtet werden soll. Damit sollten in Zukunft vor Ort...
von Tobias Borgers | Aug. 24, 2023 | Boehringer
Tp provide superior treatment options for patients navigating the complexities of diabetes Mumbai-based pharma major Lupin has announced the acquisition of diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim International GmbH (Boehringer...
